Press Releases

Press Releases

February 18, 2020
Webcast scheduled for Tuesday, February 25 at 4:30 p.m. Eastern Time BOSTON , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , announced today that it will host a live webcast on Tuesday, February 25 at 4:30 p.m.
February 13, 2020
BOSTON , Feb. 13, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , today announced the appointment of Amber Salzman , Ph.D., to the Company’s Board of Directors, expanding the board to 11 members. Dr.
January 28, 2020
Favorable safety and tolerability were observed P rimary and multiple secondary endpoints were met with significant reduction in triglyceride levels, additional lipid parameters and ANGPTL3 BOSTON and CARLSBAD, Calif. , Jan. 28, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.
January 22, 2020
Favorable safety and tolerability were demonstrated in hypertriglyceridemia patients in the study Primary and key secondary endpoints were met with significant reduction in apoC-III and triglyceride levels More than 90% of patients achieved serum triglycerides ≤ 150 mg/dL at the highest monthly
January 10, 2020
BOSTON and CARLSBAD, Calif. , Jan. 10, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the initiation of the CARDIO-TTRansform Phase 3 cardiovascular
January 2, 2020
Patients treated with AKCEA-APO(a)-L Rx received pre-specified endpoints for Lp(a) levels with favorable safety and tolerability profile Global Lp(a)HORIZON Phase 3 cardiovascular outcomes study underway BOSTON and CARLSBAD, Calif. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.
December 18, 2019
Data from Phase 2 clinical trial of AKCEA-APOCIII-LRx anticipated in early 2020 BOSTON and CARLSBAD, Calif. , Dec. 18, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc.
December 16, 2019
Lynne Parshall appointed chair and Barbara Yanni joins as new member of the Akcea board BOSTON , Dec. 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , today announced the appointments of Lynne Parshall , J.D., as chair
December 4, 2019
Alex Howarth joins Akcea from Lycera, bringing more than 25 years of experience in the biopharmaceutical sector BOSTON, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc.
November 25, 2019
BOSTON and CARLSBAD, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced initiation of the NEURO-TTRansform Phase 3 clinical trial for